Skip to main content

Table 4 Overview of studies evaluating different nCRT regimes for EC

From: Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus

Author (year) N° of patients Study design Histology RTx CTx regime Median OS in months Local failure rate pCR rate Hemato-logic toxicity (≥ III°)
Bates [8] (1996) 35 Phase 2 80% SCC 45 Gy (25 Fx) Cisplatin 5FU 25.8 7% 51% 17%
Tepper [2] (2008) 30 (trimodal therapy) Phase 3 23% SCC 50.4 Gy (28 Fx) Cisplatin 5FU 53.8 13% 40% 57%
Bosset [18] (1997) 143 (trimodal therapy) Phase 3 100% SCC 18.5 Gy (5 Fx) Cisplatin (0–2 days before first day of radiotherapy) 18.6 26%
van Hagen; Shapiro [3, 10] (2012; 2015) 178 (trimodal therapy) Phase 3 23% SCC 41.4 Gy (23 Fx) Carboplatin Paclitaxel 48.6 (all)
81.6 (SCC)
22% 29% (all)
49% (SCC)
8%
Bedenne [11] (2007) 129 (trimodal therapy) Phase 3 89% SCC 46 Gy (23 Fx) or 15 Gy (5 Fx) – week 1 + 4 Cisplatin 5-Fluoruracil 17.7 33.6%
Urba [19] (2003) 69 Phase 2 14% SCC 45 Gy (30 Fx) – twice daily Cisplatin Paclitaxel 24 22% 13%a
Blom [4] (2014) 165 Retro-spective analysis 24% SCC 1. 50.4 Gy (28 Fx)
2. 41.4 Gy (23 Fx)
1. Cisplatin 5-Fluoruracil
2. Carboplatin Paclitaxel
Not reached after 3 years 38%
24%
1.15%a
2.2% a
van Meerten [14] (2006) 54 Phase 2 22% SCC 41.4 Gy (23 Fx) Carboplatin Pacliataxel Not reached after median follow up of 31 months 13% 25% 25% a
This analysis 51 Retro-spective analysis 100% SCC 1. 45 Gy (25 Fx)
2. 41.4 Gy (23 Fx)
1. Cisplatin 5-Fluoruracil
2. Carboplatin Paclitaxel
1. 40.1
2. 23.9
1. 34%
2. 21%
1. 38%
2. 26%
1. 58%
2. 20%
  1. a neutropenia, RTx radiotherapy, CTx chemotherapy, SCC squamous cell carcinoma, Fx fractions